ReWalk Featured in Details of Department of Veterans Affairs' National Multi-Center Clinical Exoskeleton Trial

Six ReWalk Exoskeleton Systems Have Been Shipped for the Initial Phase of Four-Year VA Study

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb. 3, 2016 /PRNewswire/ -- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "Company"), the leading global exoskeleton developer and manufacturer, announced that the Department of Veterans Affairs ("VA") has publicly listed details of a national, multi-center study utilizing the Company's Personal 6.0 Exoskeleton Systems. The VA released full details of the study titled, "Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life" on the clinical trials section of the National Institutes of Health (NIH) website (www.clinicaltrials.gov Identifier: NCT02658656).


Several key components of the study outlined by the VA, include:

Enrollment of 160 participants nationwide
Eligibility criteria for study participants
Study start date: October 2016
Locations of six participating VA Medical Centers with Spinal Cord Injury Services in California, Florida, Massachusetts, Texas and Virginia
It was announced in January that the VA awarded a delivery order to Veterans Healthcare Supply Solutions (VHSS), the Service Disabled Veteran Owned Small Business (SDVOSB) authorized distributor of ReWalk Robotics, for six ReWalk exoskeleton systems to support this first-of-its-kind national study. ReWalk is the only FDA cleared exoskeleton technology for individuals with spinal cord injury. The Company has already shipped the order of six systems for the multi-center trial to the VA, and continues to work in coordination with the department as the study leads prepare for its launch this year.

"This VA clinical trial is groundbreaking in both its purpose and scope, and will undoubtedly provide a wealth of quality research data to the department's already impressive research," said ReWalk CEO Larry Jasinski. "ReWalk is glad to provide our technology to enable this critical national study."

The Department of Veterans Affairs is the largest single healthcare provider to persons with Spinal Cord Injury (SCI) in the United States. This is the first study in the United States to examine the impact of exoskeleton use in a home or daily life setting. ReWalk has Class II FDA clearances for exoskeleton use in the rehabilitation and personal setting, with the latter intended for home and community use.

About ReWalk Personal 6.0
ReWalk Personal 6.0 is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright and walk. The system provides user-initiated mobility through the integration of a wearable brace support, a computer-based control system and motion sensors. The system allows independent, controlled walking while mimicking the natural gait patterns of the legs. The ReWalk device is the most studied exoskeleton in the industry. Studies have identified a number of health benefits including: improved bladder and bowel function, improved mental health, improved sleep, reduced fatigue, decreased body fat, decreased pain and improved posture and balance.

About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Featured Product

Universal Robots Add a Sense of Touch in New e-Series Cobots with  Built-in Force/Torque Sensor and Re-Designed User Interface

Universal Robots Add a Sense of Touch in New e-Series Cobots with Built-in Force/Torque Sensor and Re-Designed User Interface

With the new e-Series cobot line, Universal Robots raises the bar for cobots, adding unique new features while significantly strengthening the four core principles defining collaborative robots: fast set-up, easy programming, flexible deployment, and safe operation. With a new built-in, tool-centric Force/Torque sensor the e-Series is ready to take on applications requiring force control right out of the box. A repeatability of 30 micron means the new cobots are suitable for very precise finishing, assembly and electronics tasks. A re-designed user interface decreases cognitive load and expedites program development, while a new externally accessible, 500Hz system bus enables more complex motion control algorithms or profiles.